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OBJECTIVES:  
To find the incidence of cisplatin induced sensorineural hearing loss, the  
correlation between cumulative dose of chemotherapy  and hearing loss, and the 
influence of age and time on the same. 
METHODS: 
Observational study. Children above 5 years with malignancies other than head and 
neck malignancies and planned for or undergoing chemotherapy with cisplatin from 
January 2012 were informed about the study, consented and recruited. They were 
then followed up for a period of 12 weeks. Before the administration of cisplatin, 
these patients are seen in the ENT department, a targeted history and examination is 
done and hearing assessment is performed which includes an Audiogram, 
Tympanometry and OAE.  Cisplatin was administered according to protocol and 
were called back after 6 weeks and 12 weeks for a repeat evaluation and hearing 
assessment.  
RESULTS: 
                          . 
       By 6 weeks, 17 developed grade 1 hearing loss and 1 developed grade 2 hearing loss. 
At the end of 3 months,  63%  patients  developed grade 1 hearing loss , 20 %  grade 2 
and 5 %  grade .40 % of those above 15 years had normal hearing as against only 9% in 
age group 5-10 years. 10-15 year age group showed a 9.5% incidence of hearing loss. 
49% of patients who were exposed to higher doses (34 mg/m2) developed sensorineural 
hearing loss as against 11 % in other groups. 
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